Over a week ago
Recommendations
BTIG analysts compiled a…
BTIG analysts compiled a list of companies in its coverage that may have potential exposure to SVB Financial (SIVB), either through loan agreements, revolving credit facilities, and/or transactions. The list includes iRhythm Technologies (IRTC), AtriCure (ATRC), ViewRay (VRAY), Treace Medical (TMCI), Vericel (VCEL), Organogenesis (ORGO), Humacyte (HUMA) and Lensar (LNSR). The firm is not changing its estimates or ratings at this time.
Show Hide Related Items >> <<
03/07/23 ViewRay announces Czech Ministry of Health approval of MRIdian purchase 01/20/23 ViewRay enters cooperation agreement with Hudson Executive Capital 01/12/23 ViewRay announces publication on MRIdian MRI-Guidance in SBRT 01/09/23 ViewRay CFO to step down, William Burke to succeed 01/10/23 Vericel expects MACI arthroscopic commercial launch in 2024 12/29/22 MediWound confirms FDA approval of NexoBrid triggers $7.5M milestone 12/29/22 Vericel announces FDA approval of NexoBrid for severe thermal burns 03/03/23 Treace Medical settles lawsuit against Fusion Orthopedics 02/09/23 Treace Medical presents updated ALIGN3D interim data 12/19/22 Treace Medical granted two bone positioning device patents from USPTO 11/28/22 Treace Medical announces bunion treatment SpeedPlate gets 510k clearance 03/10/23 Bank of England seeks to place Silicon Valley Bank UK into insolvency 03/10/23 Aptose Biosciences says immaterial financial exposure to Silicon Valley Bank 03/10/23 Paycor says no cash deposits or securities held at Silicon Valley Bank 03/10/23 Oncorus informs investors of holdings with SVB Financial 03/03/23 S&P announces changes to S&P 400, 600 indices at open on 3/20 03/01/23 Organogenesis reports interim analysis of knee osteoarthritis trial 03/10/23 iRhythm provides update on investments with SVB Financial 03/06/23 iRhythm announces results of multiple new studies at ACC.23/WCC 01/09/23 iRhythm shares preliminary Q4 highlights, business update 11/06/22 iRhythm announces new health economic analysis of mSToPS study 01/24/23 Humacyte announces publication of 6-year outcomes in Phase 2 study of HAV 12/13/22 Humacyte hosts KOL webinar on vascular trauma 11/10/22 Humacyte expects cash to fund operations through 2024 11/07/22 Humacyte presents six-month HAV CABG data at American Heart Association 01/31/23 AtriCure announces first patient treated in LeAAPS trial 02/24/23 Canaccord iRhythm price target raised to $143 from $135 at Canaccord 02/07/23 Wells Fargo iRhythm initiated with an Overweight at Wells Fargo 12/12/22 Citi iRhythm price target lowered to $110 from $144 at Citi 11/07/22 Wolfe Research iRhythm upgraded to Peer Perform from Underperform at Wolfe Research 03/12/23 Barclays Barclays reveals software names that could be impacted by SVB 03/10/23 Maxim SVB Financial downgraded to Sell from Buy at Maxim 03/10/23 Baird West Coast REITs underperforming on SVB news, says Baird 03/10/23 Stifel Stifel says SVB fallout 'appears limited' across firm's biotech coverage 02/22/23 BTIG AtriCure price target lowered to $55 from $65 at BTIG 02/22/23 Stifel AtriCure price target lowered to $48 from $55 at Stifel 02/22/23 Canaccord AtriCure price target lowered to $74 from $81 at Canaccord 02/06/23 Canaccord AtriCure price target raised to $81 from $67 at Canaccord 01/05/23 Piper Sandler Piper Sandler bullish on ViewRay following two large MRIdian agreements 11/17/22 B. Riley ViewRay resumed with a Buy at B. Riley 11/02/22 Piper Sandler ViewRay price target raised to $6.50 from $6 at Piper Sandler 10/23/22 Piper Sandler Abstracts show superior outcomes provided by MRIdian, says Piper Sandler 09/21/22 BTIG Treace Medical price target raised to $28 from $23 at BTIG 09/21/22 Stifel Treace Medical price target raised to $27 from $24 at Stifel 07/18/22 Stifel Treace Medical price target lowered to $21 from $32 at Stifel 05/12/22 BTIG Treace Medical initiated with a Buy at BTIG 01/31/23 Truist Vericel price target raised to $29 from $25 at Truist 01/03/23 H.C. Wainwright H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split 01/03/23 H.C. Wainwright Vericel price target raised to $37 from $35 at H.C. Wainwright 12/30/22 TD Cowen MediWound price target raised to $25 from $6 at Cowen 11/10/22 BTIG Organogenesis downgraded to Neutral from Buy at BTIG 08/10/22 Oppenheimer Oppenheimer downgrades Organogenesis to Perform on lowered guidance 08/10/22 Oppenheimer Organogenesis downgraded to Perform from Outperform at Oppenheimer 12/19/22 TD Cowen Humacyte price target lowered to $5 from $8 at Cowen 11/10/22 Piper Sandler Humacyte price target lowered to $2.75 from $3.50 at Piper Sandler 10/12/22 Piper Sandler CMS proposal a positive for Med Tech sector, says Piper Sandler 08/12/22 Piper Sandler Humacyte price target lowered to $3.50 from $4.00 at Piper Sandler 04/19/22 BTIG J&J results will be viewed favorably for MedTech group, says BTIG 02/27/23 ViewRay sees FY23 sees total revenue increase of 25%-40% 02/27/23 ViewRay reports Q4 EPS (15c), consensus (16c) 01/09/23 ViewRay reports preliminary Q4 revenue $35M, consensus $32.67M 11/01/22 ViewRay narrows FY22 revenue view to $94M-$104M from $90M-$104M 02/23/23 Vericel sees F Y23 revenue $180M-$188M, consensus $192.58M 02/23/23 Vericel reports Q4 EPS 12c, consensus 3c 01/10/23 Vericel sees 2022 revenue $164M-$165M, consensus $164.62M 11/09/22 Vericel sees FY22 revenue $164M-$166M, consensus $178.34M 03/07/23 Treace Medical sees FY23 revenue $$187M-$193M, consensus $174.99M 03/07/23 Treace Medical reports Q4 EPS (8c), consensus (14c) 01/09/23 Treace Medical sees Q4 revenue $49.1M-$49.6M, consensus $44.8M 11/08/22 Treace Medical raises FY22 revenue view to $135M-$138M from $130M-$134M 03/10/23 Compugen considers exposure to SVB Financial as immaterial 01/19/23 SVB Financial reports Q4 EPS $4.62, consensus $5.27 10/20/22 SVB Financial reports Q3 EPS $7.21, consensus $6.95 02/14/23 Lensar reports Q4 revenue $10.2M, consensus $10M 02/23/23 iRhythm Sees FY23 revenue $475M-$485M, consensus $485.6M 02/23/23 iRhythm reports Q4 EPS (67c), consensus (62c) 11/01/22 iRhythm cuts FY22 revenue view to $407M-$411M from $415M-$420M 11/01/22 iRhythm reports Q3 adjusted EPS (63c), consensus (83c) 11/10/22 Humacyte reports Q3 EPS (25c), consensus (21c) 09/23/22 Humacyte announces presentations by Ukrainian surgeons on use of HAV 02/21/23 AtriCure sees FY23 adjusted EPS ($1.19)-($1.14), consensus (84c) 02/21/23 AtriCure reports Q4 adjusted EPS (9c), consensus (18c) 01/09/23 AtriCure sees FY22 EPS ($1.10)-($1.12), consensus ($1.10) 01/09/23 AtriCure sees FY23 revenue $380M-$387M, consensus $380.03M
Earnings
Sees FY23 gross margin…
Sees FY23 gross margin expected to be in the high-60% range. Adjusted EBITDA margin expected to be in the mid-teens % range.
Show Hide Related Items >> <<
01/10/23 Vericel expects MACI arthroscopic commercial launch in 2024 12/29/22 MediWound confirms FDA approval of NexoBrid triggers $7.5M milestone 12/29/22 Vericel announces FDA approval of NexoBrid for severe thermal burns 01/31/23 Truist Vericel price target raised to $29 from $25 at Truist 01/03/23 H.C. Wainwright H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split 01/03/23 H.C. Wainwright Vericel price target raised to $37 from $35 at H.C. Wainwright 12/30/22 TD Cowen MediWound price target raised to $25 from $6 at Cowen 02/23/23 Vericel reports Q4 EPS 12c, consensus 3c 01/10/23 Vericel sees 2022 revenue $164M-$165M, consensus $164.62M 11/09/22 Vericel sees FY22 revenue $164M-$166M, consensus $178.34M 11/09/22 Vericel reports Q3 EPS (14c), consensus (10c) 01/12/23 Biotech Alert: Searches spiking for these stocks today
Earnings
Reports Q4 revenue…
Reports Q4 revenue $52.7M, consensus $52.94M. "The Company delivered strong financial and business results to end the year as we generated record quarterly MACI and total revenue and another quarter of profitability," said Nick Colangelo, President and CEO of Vericel. "We also achieved significant development milestones for the Company with the approval of NexoBrid and an accelerated regulatory pathway for the MACI arthroscopic delivery program. Based on our current portfolio and anticipated new product launches, we believe that the Company is well-positioned to continue to deliver strong revenue and profit growth over the long term."
Show Hide Related Items >> <<
01/10/23 Vericel expects MACI arthroscopic commercial launch in 2024 12/29/22 MediWound confirms FDA approval of NexoBrid triggers $7.5M milestone 12/29/22 Vericel announces FDA approval of NexoBrid for severe thermal burns 01/31/23 Truist Vericel price target raised to $29 from $25 at Truist 01/03/23 H.C. Wainwright H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split 01/03/23 H.C. Wainwright Vericel price target raised to $37 from $35 at H.C. Wainwright 12/30/22 TD Cowen MediWound price target raised to $25 from $6 at Cowen 01/10/23 Vericel sees 2022 revenue $164M-$165M, consensus $164.62M 11/09/22 Vericel sees FY22 revenue $164M-$166M, consensus $178.34M 11/09/22 Vericel reports Q3 EPS (14c), consensus (10c) 01/12/23 Biotech Alert: Searches spiking for these stocks today
Over a month ago
Recommendations
Truist analyst Samuel…
Truist analyst Samuel Brodovsky raised the firm's price target on Vericel to $29 from $25 but keeps a Hold rating on the shares as part of a broader research note previewing Q4 earnings in MedTech. The initial positive stock move in reaction to MACI Arthroscopic Program performance and the company's positive addressable market updates has faded more recently, and the firm is looking for increased visibility around revenue acceleration from NexoBrid, which could be a late 2023 catalyst for Vericel, the analyst tells investors in a research note.
Show Hide Related Items >> <<
01/10/23 Vericel expects MACI arthroscopic commercial launch in 2024 12/29/22 MediWound confirms FDA approval of NexoBrid triggers $7.5M milestone 12/29/22 Vericel announces FDA approval of NexoBrid for severe thermal burns 08/03/22 MediWound announces FDA acceptance of BLA for NexoBrid 01/03/23 H.C. Wainwright H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split 01/03/23 H.C. Wainwright Vericel price target raised to $37 from $35 at H.C. Wainwright 12/30/22 TD Cowen MediWound price target raised to $25 from $6 at Cowen 11/10/22 H.C. Wainwright Vericel price target lowered to $35 from $53 at H.C. Wainwright 01/10/23 Vericel sees 2022 revenue $164M-$165M, consensus $164.62M 11/09/22 Vericel sees FY22 revenue $164M-$166M, consensus $178.34M 11/09/22 Vericel reports Q3 EPS (14c), consensus (10c) 08/03/22 Vericel maintains 2022 revenue view $178M-$189M, consensus $182.2M 01/12/23 Biotech Alert: Searches spiking for these stocks today
On The Fly
Show Hide Related Items >> <<
01/10/23 Vericel expects MACI arthroscopic commercial launch in 2024 12/29/22 MediWound confirms FDA approval of NexoBrid triggers $7.5M milestone 12/29/22 Vericel announces FDA approval of NexoBrid for severe thermal burns 08/03/22 MediWound announces FDA acceptance of BLA for NexoBrid 12/12/22 Galera Therapeutics submits NDA for avasopasem for SOM 11/09/22 Galera Therapeutics expects cash to fund operations into 2H23 10/26/22 Galera Therapeutics presents Phase 3 ROMAN long-term follow-up data 09/01/22 Galera Therapeutics appoints Eugene Kennedy as CMO EIGR Eiger BioPharmaceuticals 12/27/22 Eiger BioPharmaceuticals director buys $128K in common stock 12/08/22 Eiger BioPharma's lonafarnib meets endpoints in Phase 3 HDV trial 11/03/22 Eiger expects cash and equivalents to fund operations through 2024 10/05/22 Eiger sees reporting topline data from D-LIVR study for HDV by year-end 12/29/22 Cellectis, Primera Therapeutics to partner on gene editing platform 12/28/22 Cellectis enters into EUR 40M credit facility with EIB 12/13/22 Cellectis announces preliminary data for UCART22, UCART123 11/10/22 Cellectis presents preclinical data on TALEN-edited Smart CAR T-cells ACHV Achieve Life Sciences 01/09/23 Achieve Life Sciences announces last subject dosed in Phase 3 ORCA-3 trial 12/21/22 Achieve Life Sciences granted U.S. patent for cytisinicline formulation 11/08/22 Achieve Life achieves early completion of target enrollment in ORCA-V1 trial 09/27/22 Achieve Life announces completion of enrollment for Phase 3 ORCA-3 trial 11/28/22 Citi Galera Therapeutics price target lowered to $18 from $20 at Citi 05/27/22 BofA Galera Therapeutics downgraded to Underperform from Neutral at BofA 12/14/22 Citi Cellectis price target lowered to $24 from $36 at Citi 08/18/22 Citi Cellectis price target raised to $36 from $34 at Citi 05/18/22 Baird Cellectis upgraded to Outperform at Baird on valuation 'backstop' 05/18/22 Baird Cellectis upgraded to Outperform from Neutral at Baird ACHV Achieve Life Sciences 11/16/22 Maxim Achieve Life Sciences price target lowered to $8 from $21 at Maxim 11/15/22 Oppenheimer Achieve Life Sciences price target lowered to $20 from $27 at Oppenheimer 04/27/22 Oppenheimer Achieve Life Sciences price target raised to $27 from $23 at Oppenheimer EIGR Eiger BioPharmaceuticals 01/03/23 BTIG Axsome Therapeutics named Top Pick for first half of 2023 at BTIG 12/12/22 BTIG Eiger BioPharmaceuticals price target lowered to $9 from $48 at BTIG 12/09/22 Baird Eiger BioPharmaceuticals price target lowered to $3 from $29 at Baird 12/09/22 Citi Eiger BioPharmaceuticals price target lowered to $4 from $23 at Citi 01/03/23 H.C. Wainwright H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split 01/03/23 H.C. Wainwright Vericel price target raised to $37 from $35 at H.C. Wainwright 12/30/22 TD Cowen MediWound price target raised to $25 from $6 at Cowen 11/10/22 H.C. Wainwright Vericel price target lowered to $35 from $53 at H.C. Wainwright 01/10/23 Vericel sees 2022 revenue $164M-$165M, consensus $164.62M 11/09/22 Vericel sees FY22 revenue $164M-$166M, consensus $178.34M 11/09/22 Vericel reports Q3 EPS (14c), consensus (10c) 08/03/22 Vericel maintains 2022 revenue view $178M-$189M, consensus $182.2M 11/09/22 Galera Therapeutics reports Q3 EPS (60c), consensus (52c) 08/09/22 Galera Therapeutics reports Q2 EPS (54c), consensus (53c) EIGR Eiger BioPharmaceuticals 12/15/22 Eiger BioPharmaceuticals CEO David Cory resigns, David Apelian named Interim CEO 11/03/22 Eiger BioPharmaceuticals reports Q3 EPS (62c), consensus (52c) 08/04/22 Eiger BioPharmaceuticals reports Q2 EPS (51c), consensus (61c) 11/03/22 Cellectis reports Q3 EPS (63c), consensus (45c) 08/04/22 Cellectis reports Q2 EPS (88c), consensus (56c) ACHV Achieve Life Sciences 11/14/22 Achieve Life Sciences reports Q3 EPS ($1.35), consensus ($1.13) 01/12/23 Biotech Alert: Searches spiking for these stocks today EIGR Eiger BioPharmaceuticals 12/12/22 Biotech Alert: Searches spiking for these stocks today 12/29/22 Fly Intel: After-Hours Movers
Hot Stocks
Recent Business…
Recent Business Highlights and Updates: Following a Type C meeting with the FDA, the Company is planning to initiate a human factors validation study to support expanding the MACI label to include arthroscopic administration of MACI for the treatment of cartilage defects of the knee and now anticipates an accelerated potential commercial launch of arthroscopic MACI in 2024; Announced FDA approval of NexoBrid on December 28, 2022 for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns, with U.S. commercial availability expected in the second quarter of 2023; Expect to hold a pre-IND meeting with the FDA in the first half of 2023 to discuss the MACI development program for the treatment of cartilage defects in the ankle. "We made tremendous progress advancing our pipeline and expanding our business in 2022, highlighted by an accelerated regulatory pathway for the MACI arthroscopic delivery program and the recent approval of NexoBrid," said Nick Colangelo, President and CEO of Vericel. "We also had very strong MACI performance to close the year and we look forward to building on this momentum in 2023 across both of our franchises, as we expect accelerating total revenue growth this year and further acceleration in 2024 driven by a full year of NexoBrid on the market and the planned launch of arthroscopic MACI."
Show Hide Related Items >> <<
12/29/22 MediWound confirms FDA approval of NexoBrid triggers $7.5M milestone 12/29/22 Vericel announces FDA approval of NexoBrid for severe thermal burns 08/03/22 MediWound announces FDA acceptance of BLA for NexoBrid 07/21/22 Vericel publishes BRCA study results of burn patients treated with Epicel 01/03/23 H.C. Wainwright H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split 01/03/23 H.C. Wainwright Vericel price target raised to $37 from $35 at H.C. Wainwright 12/30/22 TD Cowen MediWound price target raised to $25 from $6 at Cowen 11/10/22 H.C. Wainwright Vericel price target lowered to $35 from $53 at H.C. Wainwright 01/10/23 Vericel sees 2022 revenue $164M-$165M, consensus $164.62M 11/09/22 Vericel sees FY22 revenue $164M-$166M, consensus $178.34M 11/09/22 Vericel reports Q3 EPS (14c), consensus (10c) 08/03/22 Vericel maintains 2022 revenue view $178M-$189M, consensus $182.2M
Earnings
Total net revenue for…
Total net revenue for full-year 2022 expected to be approximately $164 to $165 million; MACI net revenue for full-year 2022 expected to be approximately $132 million; Burn Care net revenue for full-year 2022 expected to be approximately $32.5 million; Fourth quarter MACI revenue growth expected to be approximately 24% versus prior year; Expect tenth straight quarter with positive adjusted EBITDA and Operating Cash Flow; As of December 31, 2022, the Company had approximately $140 million in cash and investments and no debt.
Show Hide Related Items >> <<
12/29/22 MediWound confirms FDA approval of NexoBrid triggers $7.5M milestone 12/29/22 Vericel announces FDA approval of NexoBrid for severe thermal burns 08/03/22 MediWound announces FDA acceptance of BLA for NexoBrid 07/21/22 Vericel publishes BRCA study results of burn patients treated with Epicel 01/03/23 H.C. Wainwright H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split 01/03/23 H.C. Wainwright Vericel price target raised to $37 from $35 at H.C. Wainwright 12/30/22 TD Cowen MediWound price target raised to $25 from $6 at Cowen 11/10/22 H.C. Wainwright Vericel price target lowered to $35 from $53 at H.C. Wainwright 11/09/22 Vericel sees FY22 revenue $164M-$166M, consensus $178.34M 11/09/22 Vericel reports Q3 EPS (14c), consensus (10c) 08/03/22 Vericel maintains 2022 revenue view $178M-$189M, consensus $182.2M 08/03/22 Vericel reports Q2 EPS (19c), consensus (12c)
Recommendations
H.C. Wainwright analyst…
H.C. Wainwright analyst Swayampakula Ramakanth adjusted the firm's price target on MediWound (MDWD) to $23 from $5.50 and keeps a Buy rating on the shares to account for the reverse split of 1 for 7 shares that became effective on December 20 and the approval of NexoBrid by the FDA on December 29. While awaiting pricing details from Vericel (VCEL) management, Ramakanth currently assumes initial revenue of $6,500 per patient per burn treatment and assumes "meaningful" NexoBrid revenues to start from Q3 of 2023, the analyst noted.
Show Hide Related Items >> <<
08/03/22 MediWound announces FDA acceptance of BLA for NexoBrid 07/21/22 Vericel publishes BRCA study results of burn patients treated with Epicel 12/29/22 MediWound confirms FDA approval of NexoBrid triggers $7.5M milestone 12/29/22 Vericel announces FDA approval of NexoBrid for severe thermal burns 12/29/22 MediWound receives FDA approval of NexoBrid for treatment of severe burns 12/23/22 MediWound announces marketing approval of NexoBrid in Japan 12/30/22 TD Cowen MediWound price target raised to $25 from $6 at Cowen 12/29/22 Oppenheimer MediWound NexoBrid U.S. approval came ahead of schedule, says Oppenheimer 12/22/22 Maxim MediWound initiated with a Buy at Maxim 12/21/22 Oppenheimer MediWound price target raised to $63 from $9 at Oppenheimer 01/03/23 H.C. Wainwright Vericel price target raised to $37 from $35 at H.C. Wainwright 11/10/22 H.C. Wainwright Vericel price target lowered to $35 from $53 at H.C. Wainwright 11/09/22 BTIG Vericel downgraded to Neutral from Buy at BTIG 11/09/22 Vericel sees FY22 revenue $164M-$166M, consensus $178.34M 11/09/22 Vericel reports Q3 EPS (14c), consensus (10c) 08/03/22 Vericel maintains 2022 revenue view $178M-$189M, consensus $182.2M 08/03/22 Vericel reports Q2 EPS (19c), consensus (12c) 11/15/22 MediWound reports Q3 EPS (13c), consensus (8c) 08/09/22 MediWound reports Q2 EPS (13c), consensus (10c)
Recommendations
H.C. Wainwright analyst…
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on Vericel to $37 from $35 and keeps a Buy rating on the shares following the FDA approval of NexoBrid. The drug received a wider label than expected as it can be applied up to two applications with an initial application that can cover an area of up to 15% of body surface area and a second application within 24 hours to cover an area of up to 20% of body surface area, Ramakanth tells investors in a research note. Based on the collaboration agreement with MediWound, Vericel is expected to pay a milestone payment of $7.5M in Q1, the analyst adds.
Show Hide Related Items >> <<
12/29/22 MediWound confirms FDA approval of NexoBrid triggers $7.5M milestone 12/29/22 Vericel announces FDA approval of NexoBrid for severe thermal burns 08/03/22 MediWound announces FDA acceptance of BLA for NexoBrid 07/21/22 Vericel publishes BRCA study results of burn patients treated with Epicel 12/30/22 TD Cowen MediWound price target raised to $25 from $6 at Cowen 11/10/22 H.C. Wainwright Vericel price target lowered to $35 from $53 at H.C. Wainwright 11/09/22 BTIG Vericel downgraded to Neutral from Buy at BTIG 11/09/22 Truist Vericel downgraded to Hold from Buy at Truist 11/09/22 Vericel sees FY22 revenue $164M-$166M, consensus $178.34M 11/09/22 Vericel reports Q3 EPS (14c), consensus (10c) 08/03/22 Vericel maintains 2022 revenue view $178M-$189M, consensus $182.2M 08/03/22 Vericel reports Q2 EPS (19c), consensus (12c)
Recommendations
Cowen analyst Joshua…
Cowen analyst Joshua Jennings raised the firm's price target on MediWound (MDWD) to $25 from $6 and keeps an Outperform rating on the shares after the FDA approved NexoBrid and triggered a $7.5M milestone from Vericel (VCEL). MediWound will benefit from high-single digit royalties on U.S. Nexobrid sales, also recently announced regulatory approvals in India and Japan and should secure EMA pediatric labeling in Q1, Jennings tells investors.
Show Hide Related Items >> <<
08/03/22 MediWound announces FDA acceptance of BLA for NexoBrid 07/21/22 Vericel publishes BRCA study results of burn patients treated with Epicel 12/29/22 MediWound confirms FDA approval of NexoBrid triggers $7.5M milestone 12/29/22 Vericel announces FDA approval of NexoBrid for severe thermal burns 12/29/22 MediWound receives FDA approval of NexoBrid for treatment of severe burns 12/23/22 MediWound announces marketing approval of NexoBrid in Japan 12/29/22 Oppenheimer MediWound NexoBrid U.S. approval came ahead of schedule, says Oppenheimer 12/22/22 Maxim MediWound initiated with a Buy at Maxim 12/21/22 Oppenheimer MediWound price target raised to $63 from $9 at Oppenheimer 11/16/22 H.C. Wainwright MediWound price target lowered to $5.50 from $6 at H.C. Wainwright 11/10/22 H.C. Wainwright Vericel price target lowered to $35 from $53 at H.C. Wainwright 11/09/22 BTIG Vericel downgraded to Neutral from Buy at BTIG 11/09/22 Truist Vericel downgraded to Hold from Buy at Truist 10/13/22 Stephens Vericel resumed with an Overweight at Stephens 11/09/22 Vericel sees FY22 revenue $164M-$166M, consensus $178.34M 11/09/22 Vericel reports Q3 EPS (14c), consensus (10c) 08/03/22 Vericel maintains 2022 revenue view $178M-$189M, consensus $182.2M 08/03/22 Vericel reports Q2 EPS (19c), consensus (12c) 11/15/22 MediWound reports Q3 EPS (13c), consensus (8c) 08/09/22 MediWound reports Q2 EPS (13c), consensus (10c)